Loading quotes...
Forecast
The analysts' average price target is €9.80 (+536.36%). The median is €9.80 (+536.36%).
| Buy |
7 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -6.07M | 31.38% |
| EBITDA | -6.07M | 32.74% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €12.6M |
Number of shares | 7.99M |
52-week high/low | €5.81 - €1.57 |
| Dividends | No |
Beta | 0.56 |
P/E ratio | -0.39 |
PEG ratio | 0.00 |
P/B ratio | 0.72 |
P/S ratio | 0.00 |
Company profile
| Name | Cellectar Biosciences |
| CEO | James V. Caruso |
| Headquarters | Florham Park,
nj USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 11 |
